Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

Core Insights - Azitra, Inc. announced positive preclinical progress for its ATR-01 program targeting ichthyosis vulgaris, a genetic disorder affecting approximately 1.3 million people in the U.S. [1][2] - The ATR-01 program utilizes an engineered strain of S. epidermidis, ATR01-616, which secretes functional filaggrin, showing promising results in preclinical models [2][3] - The company plans to present detailed data at the BIO-Europe conference in November 2025 and aims to submit an IND for ATR-01 in 2026 [1][3] Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a rare skin disease [3] - The company also has an advanced program, ATR-04, for treating EGFR inhibitor-associated rash, which has received Fast Track designation from the FDA [3] - Azitra's programs are developed from a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by artificial intelligence and machine learning [3]